CG Oncology (NASDAQ:CGON) Upgraded by Wall Street Zen to “Hold” Rating

CG Oncology (NASDAQ:CGON) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday.

Several other equities analysts have also recently commented on CGON. Royal Bank Of Canada increased their target price on CG Oncology from $61.00 to $73.00 and gave the company an “outperform” rating in a research note on Wednesday, January 21st. Weiss Ratings reiterated a “sell (d-)” rating on shares of CG Oncology in a research note on Wednesday, January 21st. The Goldman Sachs Group reiterated a “buy” rating and set a $82.00 target price on shares of CG Oncology in a research note on Monday, January 12th. HC Wainwright increased their target price on CG Oncology from $80.00 to $100.00 and gave the company a “buy” rating in a research note on Tuesday. Finally, Morgan Stanley set a $93.00 price objective on CG Oncology in a research note on Friday, January 9th. Eleven research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $70.67.

CG Oncology Stock Down 1.3%

Shares of NASDAQ:CGON opened at $67.70 on Friday. CG Oncology has a 52-week low of $17.10 and a 52-week high of $71.90. The company has a 50 day moving average of $60.65 and a two-hundred day moving average of $49.37. The company has a market capitalization of $5.72 billion, a price-to-earnings ratio of -32.71 and a beta of 0.70.

CG Oncology (NASDAQ:CGON) last released its earnings results on Friday, February 27th. The company reported ($0.51) EPS for the quarter, beating the consensus estimate of ($0.61) by $0.10. The business had revenue of $2.32 million for the quarter. On average, equities analysts anticipate that CG Oncology will post -1.31 earnings per share for the current year.

Insider Transactions at CG Oncology

In other CG Oncology news, Director James Mulay sold 1,964 shares of the stock in a transaction on Monday, March 16th. The stock was sold at an average price of $63.50, for a total value of $124,714.00. The sale was disclosed in a document filed with the SEC, which is available through this link. 7.40% of the stock is owned by company insiders.

Institutional Investors Weigh In On CG Oncology

Several large investors have recently added to or reduced their stakes in CGON. AQR Capital Management LLC acquired a new stake in CG Oncology in the first quarter worth $475,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in CG Oncology by 18.1% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 35,522 shares of the company’s stock worth $876,000 after buying an additional 5,442 shares during the period. Millennium Management LLC increased its position in CG Oncology by 139.4% in the first quarter. Millennium Management LLC now owns 596,056 shares of the company’s stock worth $14,597,000 after buying an additional 347,055 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in CG Oncology by 42.5% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 179,363 shares of the company’s stock worth $4,393,000 after buying an additional 53,461 shares during the period. Finally, Legal & General Group Plc increased its position in CG Oncology by 12.3% in the second quarter. Legal & General Group Plc now owns 44,354 shares of the company’s stock worth $1,153,000 after buying an additional 4,847 shares during the period. 26.56% of the stock is owned by institutional investors and hedge funds.

CG Oncology Company Profile

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.